| |
The "Vioxx Recall." Merck & Company's
Withdrawal of Vioxx from the Market
Merck & Company, the manufacturer of Vioxx, voluntarily
withdrew Vioxx from the market worldwide on September
30, 2004. In the recent media the withdrawal has been
referred to as the "Vioxx Recall." According
to the company's press release, the withdrawal was
based upon a recent placebo controlled efficacy study which
had to be stopped because the early data demonstrated
that those in the Vioxx group had an increased risk
for confirmed myocardial events, including heart attacks
and stroke, as well as an increased incidence of other
cardiovascular disease and adverse reactions. Merck's
announcement that it was withdrawing Vioxx, however,
also followed substantial earlier evidence including
clinical studies (including the March 2000 "VIGOR
study")and a peer reviewed published article
analyzing the study data (the August 2001 Cleveland
Clinic study, published in the Journal of American
Medical Association). This earlier study data demonstrated
a four fold increased risk of heart attack, as well
as increased incidence of stroke and other cardiovascular
disease in association with use of the drug. To learn
more about the Vioxx studies which preceded the "Vioxx
recall" you may consult the "Vioxx Clinical
Studies" page of this web site.
|  |